Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study
- PMID: 22507978
- DOI: 10.1093/eurheartj/ehs083
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study
Abstract
Aims: CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a non-CYP3A4-metabolized statin on platelet function among patients receiving clopidogrel and atorvastatin with high on-treatment platelet reactivity (HPR).
Methods and results: Percutaneous coronary intervention (PCI)-treated patients (n= 50) with HPR [20 μM adenosine diphosphate (ADP)-induced maximal platelet aggregation (MPA) >50%] were enrolled during chronic administration of atorvastatin (10 mg/day) and clopidogrel (75 mg/day) (≥6 months). They were randomly assigned to a 15-day therapy with either rosuvastatin 10 mg/day (n= 25) or pravastatin 20 mg/day (n= 25). Platelet function was assessed before and after switching by conventional aggregometry and the VerifyNow P2Y12 assay. Genotyping was performed for CYP2C19*2/*3, CYP3A5*3, and ABCB1 C3435T alleles. The primary endpoint was the absolute change in 20 μM ADP-induced MPA. After switching, MPAs after stimuli with 20 and 5 μM ADP were decreased by 6.6% (95% confidence interval: 3.2-10.1%; P < 0.001), and 6.3% (95% confidence interval: 2.5-10.2%; P = 0.002), respectively. Fifty-two P2Y12 reaction units fell (95% confidence interval: 35-70; P < 0.001) and the prevalence of HPR decreased (24%; P < 0.001). Pharmacodynamic effects were similar after rosuvastatin and pravastatin therapy. In addition to smoking status, the combination of calcium channel blocker usage and ABCB1 C3435T genotype significantly affected the change of 20 μM ADP-induced MPA.
Conclusions: Among PCI-treated patients with HPR during co-administration of clopidogrel and atorvastatin, switching to a non-CYP3A4-metabolized statin can significantly decrease platelet reactivity and the prevalence of HPR. This switching effect appears similar irrespective of the type of non-CYP3A4-metabolized statin.
Comment in
-
Blockbuster interactions: are they bad for the patient?Eur Heart J. 2012 Sep;33(17):2121-3. doi: 10.1093/eurheartj/ehs126. Epub 2012 May 21. Eur Heart J. 2012. PMID: 22613346 No abstract available.
Similar articles
-
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.Eur J Pharmacol. 2014 Feb 15;725:18-22. doi: 10.1016/j.ejphar.2014.01.006. Epub 2014 Jan 17. Eur J Pharmacol. 2014. PMID: 24444439 Clinical Trial.
-
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.J Intern Med. 2009 Nov;266(5):457-66. doi: 10.1111/j.1365-2796.2009.02119.x. Epub 2009 Jun 22. J Intern Med. 2009. PMID: 19549094 Clinical Trial.
-
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.J Atheroscler Thromb. 2014;21(2):140-50. doi: 10.5551/jat.19265. Epub 2013 Oct 18. J Atheroscler Thromb. 2014. PMID: 24140730 Clinical Trial.
-
[Statin and clopidogrel pharmacological interaction].G Ital Cardiol (Rome). 2013 Sep;14(9):574-84. doi: 10.1714/1311.14483. G Ital Cardiol (Rome). 2013. PMID: 23903277 Review. Italian.
-
Concurrent use of clopidogrel (Plavix) and atorvastatin (Lipitor) is contraindicated.S Afr Med J. 2006 Jun;96(6):474. S Afr Med J. 2006. PMID: 16841123 Review. No abstract available.
Cited by
-
Anti-platelet Therapy Resistance - Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities.J Crit Care Med (Targu Mures). 2016 Feb 9;2(1):6-15. doi: 10.1515/jccm-2015-0021. eCollection 2016 Jan. J Crit Care Med (Targu Mures). 2016. PMID: 29967831 Free PMC article.
-
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.Int J Environ Res Public Health. 2017 Mar 14;14(3):301. doi: 10.3390/ijerph14030301. Int J Environ Res Public Health. 2017. PMID: 28335443 Free PMC article. Review.
-
Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study.Clin Cardiol. 2017 Aug;40(8):605-611. doi: 10.1002/clc.22709. Epub 2017 Apr 19. Clin Cardiol. 2017. PMID: 28422300 Free PMC article. Clinical Trial.
-
Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial.Medicine (Baltimore). 2015 Dec;94(50):e2262. doi: 10.1097/MD.0000000000002262. Medicine (Baltimore). 2015. PMID: 26683949 Free PMC article. Clinical Trial.
-
Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.Eur J Clin Pharmacol. 2020 Mar;76(3):419-430. doi: 10.1007/s00228-019-02822-x. Epub 2020 Jan 2. Eur J Clin Pharmacol. 2020. PMID: 31897532
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous